Choice of TKI in Newly Diagnosed CML Patients
This is the first of two parts for the South Asia iCMLf Regional Discussion Group held on the 21st of May 2025.
Regional Expert
Dr Mipsang Lama
Clinical Hematology and
BMT Patan Hospital,
Lalitpur, Nepal
International Expert
Professor Gianantonio Rosti
IRCCS/SIRHHC Scientific Institute for Research,
Hospitalisation and Health Care,
Meldola (FC), Italy
View the second part of this discussion: 3rd Line Therapy - How do you Choose the Right Thing at the Right Time?
See all our 2025 South Asia Regional Discussion Groups on YouTube
Find all our South Asia Regional Discussion Groups on YouTube
00:00 Welcome and introduction
05:50 Overview of TKI choice for first-line therapy
07:09 Case 1 and discussion: 31yo male with total leukocite count of 121K and moderate splenomegaly
29:49 Case 2 and discussion: 18 yo male with sokal score of 0.8 (intermediate risk)
